This invention provides ex vivo methods for making modified PBMC compositions having overall anti-fugetactic properties for the effective and efficient treatment of tumors or cancers in a patient, and compositions and use thereof, following treatment with an antigen presenting cell-based vaccine against a cancer antigen.
